-transparent.png){kind=logo}
The effects of simvastatin 40 mg per day for 14 weeks on the pituitary-testis axis of 19 men with familial hypercholesterolaemia have been examined in a single-blind study. Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol and triglycerides by 45% and 30%, respectively, and significantly increased high density lipoprotein (HDL) cholesterol by 15%. The alterations, which were stable 4 weeks after the start of treatment, were not associated with any significant change in sperm quality, the seminal plasma concentrations of various sex gland products (prostate-specific acid phosphatase, polyamines, citrate, fructose, alpha-glucosidase), or the serum concentrations of cortisol, testosterone, LH, FSH, or prolactin. It is concluded that a short-term reduction in circulating LDL-cholesterol has no marked effect on testicular function or sperm quality.
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
April 1995,
The Netherlands journal of medicine,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
April 1990,
European journal of clinical investigation,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
March 1995,
British journal of clinical pharmacology,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
March 2001,
Coronary artery disease,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
August 2001,
Atherosclerosis,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
February 1988,
Atherosclerosis,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
December 2004,
Coronary artery disease,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
December 1992,
Clinical science (London, England : 1979),
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
January 2003,
Drug safety,
K Purvis, and
A Tollefsrud, and
H Rui, and
E Haug, and
J Norseth, and
L Viksmoen, and
L Ose, and
H Lund
August 2003,
Heart (British Cardiac Society),
